阿瑞匹坦一个疗程几盒？多少钱？

Aprepitant can be combined with other antiemetics to prevent acute and delayed nausea and vomiting related to HEC (including high-dose cisplatin) and MEC. This article will detail how many boxes of aprepitant are needed for a course of treatment, its price, and its medication guidance in special populations. The article covers the dosage of aprepitant treatment, the prices of different versions, and precautions for its use in specific groups of people.

How many boxes of aprepitant per course

Adults and adolescents over 12 years old

For adults and adolescents over 12 years old, when undergoing highly emetogenic chemotherapy or moderately emetogenic chemotherapy, the standard treatment plan for aprepitant is 125 mg orally on the first day, and 80 mg orally on each of the following two days. Therefore, each course of treatment requires a little more than one box of medicine, specifically a package containing 125mg*1 pill + 80mg*2 pills.

Pediatric Medication

For children 6 months to under 12 years old, the dose is adjusted according to body weight, usually 3mg/kg (maximum 125mg) on ​​the first day, and 2mg/kg (maximum 80mg) per day on the 2nd and 3rd days. In this case, more boxes of medication may be needed to cover the entire course of treatment, depending on the child's weight and doctor's advice.

How much does Aprepitant cost?

Indian Greenmark Pharmaceutical Factory Edition

The specifications of Aprepitant capsules produced by Greenmark Pharmaceutical Factory in India are 125mg 1 capsule + 80mg 2 capsules, and the price per box is about US$9. The price is relatively affordable and suitable for patients who need to take it for a long time.

Domestic generic version

In the domestic market, the first generic capsule "Oukeping" launched by Qilu Pharmaceutical and products from other manufacturers such as Zhengda Tianqing Pharmaceutical and Nanjing Entai Pharmaceutical have gradually entered the market. Due to competition from domestic generic drugs, the price has dropped compared to the original drug, but the specific price depends on local medical insurance policies and personal circumstances.

Special population use of aprepitant

Pregnant women

Animal tests have not shown aprepitant to be teratogenic, but there is insufficient human data. Pregnant women need to weigh the benefits and risks when using it. If the benefits of treatment outweigh the potential risks, it can be used under the guidance of a doctor.

Breastfeeding women

It is unclear whether aprepitant will be excreted into breast milk, so it is recommended that breastfeeding women stop breastfeeding during use. If this medication must be used, consult your doctor and consider alternative feeding methods.

The elderly and those with renal impairment

The elderly do not need to adjust the dose, but due to the general decline in physiological functions, attention should be paid to changes in liver and kidney function and the risks of combined medications. In patients with renal impairment, no dose adjustment is required and hemodialysis does not affect pharmacokinetics.

Patients with hepatic impairment

No dose adjustment is required for mild to moderate hepatic impairment, but for patients with severe hepatic impairment (Child-Pugh score greater than 9), there is insufficient data and adverse reactions need to be carefully monitored.